Implantica AG (publ.) will host its Capital Markets Day on September 9, 2026, from 14:00 to 16:30 CEST at Sergelkonferensen in Stockholm. The event will center on the company’s plans following recent FDA approval of RefluxStop®, including its U.S. market-launch strategy and the growth opportunity in a market where an estimated 78 million people in the U.S. suffer from acid reflux. Management, RefluxStop® surgeons and patients will discuss clinical and patient perspectives, while the company presents its rollout plans and next steps. The event will also be available through a live webcast.